By Tod Hoffman, Lady Davis Institute for Medical Research

The use of incretin-based drugs is not associated with an increased risk of pancreatic cancer in patients with type 2 diabetes, according to a study published in the latest issue of the British Medical Journal (BMJ).

The research was conducted by the Canadian Network for Observational Drug Effect Studies (CNODES), which used the health records of almost 1 million patients with types 2 diabetes.

Classified as: CIHR, faculty of medicine, health, Cancer, jewish general hospital, Samy Suissa, diabetes, health and lifestyle, health canada, pancreatic cancer, CNODES, drug safety
Published on: 22 Feb 2016
Back to top